IRON vs PTGX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IRON and PTGX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IRON and PTGX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its programs aim to modify the biological pathways behind red blood cell formation and function, principally heme biosynthesis and iron homeostasis. The lead pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), DISC-0974 (an anti-hemojuvelin antibody) for anemia of myelofibrosis, and DISC-3405 (an anti-TMPRSS6 antibody) being studied in conditions like polycythemia vera and sickle cell disease. The current company was formed when Disc Medicine reverse-merged into Gemini Therapeutics in December 2022 and began trading under the ticker IRON.

Full IRON guide

Protagonist Therapeutics is a Newark, California biotech that discovers oral and injectable peptide-based drugs and develops them mostly through large-pharma partners. Its two lead assets define the company: icotrokinra, an oral IL-23 receptor antagonist licensed to Johnson & Johnson and launched in the U.S. in March 2026 (branded ICOTYDE) for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic licensed to Takeda whose NDA for polycythemia vera is under FDA priority review with a target action date in the third quarter of 2026. Behind those, the pipeline includes an oral IL-17 antagonist, an oral hepcidin functional mimetic, and obesity dual and triple agonists such as PN-477, most still in early stages.

Full PTGX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IRON drivers: Bitopertin and the APOLLO Phase 3 catalyst; DISC-0974 in anemia of myelofibrosis.
• PTGX drivers: Icotrokinra (ICOTYDE) launch with J&J; Rusfertide FDA decision with Takeda.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Disc Medicine is a clinical-stage company with essentially no product revenue, so it is not profitable and its value rests on trials that can fail. For PTGX, as a partner-dependent biotech, Protagonist has limited control over commercial execution: icotrokinra's uptake and rusfertide's approval and launch sit largely with J&J and Takeda.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IRON if you believe its drivers more; PTGX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IRON and PTGX guides.

IRON. As a clinical-stage biotech, Disc has no meaningful product sales, so traditional metrics like P/E do not apply and the company is valued on its pipeline's expected value and its cash. Its roughly $791 million cash pile is large relative to its market cap, meaning a big share of the value is the balance sheet plus the option value of its programs. The market cap and share price can swing sharply around trial data and FDA decisions.

PTGX. As of June 2026, revenue was dominated by milestone and collaboration payments, including a ~$50M ICOTYDE approval milestone and a ~$200M rusfertide opt-out payment, which produced a small Q1 profit even though trailing-twelve-month results were still a net loss of roughly $115M. The ~$620M cash balance is expected to fund operations through at least 2028. Standard earnings multiples are not very meaningful here because income is lumpy and tied to one-time partner events rather than recurring product sales.

Headline figures (approximate, JULY 2026): IRON shows revenue (ttm) ~$0 (pre-revenue, clinical stage), net loss (approx, ttm) ~$180 million, cash and investments ~$791 million, net cash position ~$760 million (~$20/share); PTGX shows market cap ~$6.3B, share price ~$110, revenue (ttm) ~$74M, q1 2026 revenue ~$56.4M.

IRON and PTGX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IRON and PTGX exposure against your real portfolio. It is not an investment adviser.